Journal
CELL
Volume 179, Issue 4, Pages 880-+Publisher
CELL PRESS
DOI: 10.1016/j.cell.2019.10.002
Keywords
-
Categories
Funding
- amfAR Institute for HIV Cure Research
- University of California San Francisco-Gladstone Institutes Center for AIDS Research (NIH) [P30 AI027763]
- James B. Pendleton Charitable Trust
- NIH [R01AI109593]
- NIDCR [DP1DE024408]
- HIV/AIDS Positive Health Program of the Zuckerberg San Francisco General Hospital [NCT00187512]
Ask authors/readers for more resources
Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells to become visible to the immune system. A critical second step is killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the evolution of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, convertibleCAR-T cells, effectively kills HIV-infected, but not uninfected, CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies. convertibleCAR-T cells also kill within 48 h more than half of the inducible reservoir found in blood of HIV-infected individuals on antiretroviral therapy. The modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available